UNSPSC 51202800: Immunosupressant macrolides

This classification denotes macro-cyclic compounds that form by chain extension of multiple propionates cyclized into 12, 14, or 16-membered lactones, compounds called macrolides, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPRESSANT MACROLIDES.

UNSPSC 51202800 Immunosuppressant macrolides is a Class code that nominally addresses pharmaceutical compounds, but the recent state and local contract opportunities posted under this code show minimal alignment with immunosuppressant macrolide procurement itself. The four most recent opportunities span naloxone and drug deactivation systems (Seminole County), direct-to-manufacturer prescription program implementation (Texas HHS), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals with over-the-counter products distributed through wholesalers (Minnesota Multistate Cooperative Purchasing Alliance). The only opportunity with explicit pharmaceutical scope—the Tampa Fire Department medical supplies bid—addresses emergency consumables and equipment rather than immunosuppressant macrolides. The issuing bodies range across county health departments, state health and human services commissions, municipal fire departments, and multi-state cooperative purchasing entities, indicating fragmentation across different government service lines and procurement vehicles rather than concentrated activity around the code's stated product category.

Geographic activity in recent solicitations spans Florida (Seminole County), Texas (Texas HHS Commission), Florida again (City of Tampa), and a multi-state vehicle anchored in Minnesota with Oregon participation (MMCAP). The most concrete recent opportunity is the City of Tampa's IFB 26P00145 for medical and first aid supplies with a response deadline of March 13, 2026, and an estimated contract value of $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with contract effectiveness beginning July 1, 2026, and a two-year initial term. The Texas HHS Commission released an RFI (HHS0017013) on March 27, 2026, with a response deadline of April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Taken together, the code shows little procurement activity specifically targeting immunosuppressant macrolide products and appears to capture broader pharmaceutical, medical supply, and pharmacy benefit management solicitations that do not match the code's nominal scope.